Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 6, 2006, Pages 1103-1108

  Sarandol, Asli ^a   Sarandol, Emre ^a   Eker, Salih Saygin ^a   Karaagac, Esra Ugurlu ^a   Hizli, Banu Zafer ^a   Dirican, Melahat ^a   Kirli, Selcuk ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Aylesterase; Coronary artery disease; Lipid; Lipoprotein oxidation; Major depressive disorder; Paraoxonase

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; COPPER SULFATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OXIDATION; PREDICTION; SPECTROPHOTOMETRY;

ADULT; ANTIDEPRESSIVE AGENTS; APOLIPOPROTEINS B; ARYLDIALKYLPHOSPHATASE; C-REACTIVE PROTEIN; CARBOXYLIC ESTER HYDROLASES; CHOLESTEROL; CHOLESTEROL, HDL; DEPRESSIVE DISORDER, MAJOR; FEMALE; HOMOCYSTEINE; HUMANS; LIPOPROTEINS; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATION-REDUCTION; PHENOTYPE; PSYCHIATRIC STATUS RATING SCALES; TRIGLYCERIDES;

EID: 33745225923     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.04.012     Document Type: Article

References (39)

1. Adkins S., Gan K.N., Mody M., and La Du B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 52 (1993) 598-608
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition (1994), American Psychiatric Association, Washington, DC
3. Anisman H., and Merali Z. Cytokines, stress, and depressive illness. Brain Behav Immun 16 (2002) 513-524
4. Apter A., Laufer N., Bar-Sever M., Har-Even D., Ofek H., and Weizman A. Serum cholesterol, suicidal tendencies, impulsivity, aggression, and depression in adolescent psychiatric inpatients. Biol Psychiatry 46 (1999) 532-541
5. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., and La Du B.N. Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest 101 (1998) 1581-1590
6. Barefoot J.C., and Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation 93 (1996) 1976-1980
7. Buege J.A., and Aust S.D. Microsomal lipid peroxidation. Methods Enzymol 52 (1978) 302-310
8. Cao H., Girard-Globa A., Berthezene F., and Moulin P. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q-R polymorphism. J Lipid Res 40 (1999) 133-139
9. Deisenhammer E.A., Kramer-Reinstadler K., Liensberger D., Kemmler G., Hinterhuber H., and Fleisschhacker W.W. No evidence for an association between serum cholesterol and the course of depression and suicidality. Psychiatry Res 121 (2004) 253-261
10. DiMatteo M.R., Lepper H.S., and Croghan T.W. Depression is a risk factor for noncompliance with medical treatment. Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160 (2000) 2101-2107
11. Eckerson H.W., Wyte M.C., and La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 35 (1983) 1126-1138
12. Empena J.P., Sykes D.H., Juhan-Vague I., Arveiler D., Ferrieres J., Amouyel P., et al. Contributions of depressive mood and circulating inflammatory markers to coronary heart disease in healthy European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 111 (2005) 2299-2305
13. Frasure-Smith N., and Lesperance F. Reflections on depression as a cardiac risk factor. Psychosom Med 67 Supplement 1 (2005) S19-S25
14. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-508
15. Gan K.N., Smolen A., Eckerson H.W., and La Du B.N. Purification of human serum paraoxonase/arylesterase: evidence for one esterase catalyzing both activities. Drug Metab Dispos 19 (1991) 100-106
16. Haagen L., and Brock A. A new automated method for phenotyping arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 30 (1992) 391-395
17. Huang T.L. Serum lipid profiles in major depression with clinical subtypes, suicide attempts and episodes. J Affect Disord 86 (2005) 75-79
18. 55 Genotype. Arterioscler Thromb Vasc Biol 20 (2000) 2441-2447
19. Jong M.C., Hendriks W.L., Van Vark L.C., Dahlmans V.E., Groener J.E., and Havekes L.M. Oxidized VLDL induces less triglyceride accumulation in J774 macrophages than native VLDL due to an impaired extracellular lipolysis. Arterioscler Thromb Vasc Biol 20 (2000) 144-151
20. Joynt K.E., Whellan D.J., and O'Connor C.M. Depression and cardiovascular disease: mechanisms of interaction. Biol Psychiatry 54 (2003) 248-261
21. Jow G.M., Yang T.T., and Chen C.L. Leptin and cholesterol levels are low in major depressive disorder, but high in schizophrenia. J Affect Disord 90 (2006) 21-27
22. Kopf D., Westphal S., Luley C.W., Ritter S., Gilles M., Weber-Hamann B., et al. Lipid metabolism and insulin resistance in depressed patients. J Clin Psychopharmacol 24 (2004) 527-531
23. Lett H.S., Blumenthal J.A., Babyak M.A., Sherwood A., Strauman T., Robins C., et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med 66 (2004) 305-315
24. Mackness M.I., Harty D., Bhatnagar D., Winocour P.H., Arrol S., Ishola M., et al. Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus. Atherosclerosis 86 (1991) 193-199
25. Mackness M.I., Arrol S., Abbott C.A., and Durrington P.N. Protection of low-density lipoprotein against oxidative modification by high density lipoprotein associated paraoxonase. Atherosclerosis 104 (1993) 129-135
26. Mackness B., Durrington P., McElduff P., Yarnell J., Azam N., Watt M., et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107 (2003) 2775-2779
27. Miller G.E., Freedland K.E., Duntley S., and Carney R.M. Relation of depressive symptoms to C-reactive protein and pathogen burden (Cytomegalovirus, Herpes simplex virus, Epstein-Barr virus) in patients with earlier acute coronary syndromes. Am J Cardiol 95 (2005) 317-321
28. Mosca L., Rubenfire M., Tarshis T., Tsai A., and Pearson T. Clinical predictors of oxidized low-density lipoprotein in patients with coronary artery disease. Am J Cardiol 80 (1997) 825-830
29. Nakao M., and Yano E. Relationship between major depression and high serum cholesterol in Japanese men. Tohoku J Exp Med 204 (2004) 273-287
30. Pratt L.A., Ford D.E., Crum R.E., Armenian H.K., Gallo J.J., and Eaton W.W. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation 94 (1996) 3123-3129
31. Rozanski A., Blumenthal J.A., Davidson K.W., Saab P.G., and Kubzanskky L. The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice: the emerging field of behavioral cardiology. J Am Coll Cardiol 45 (2005) 637-651
32. Rozanski A., Blumenthal J.A., and Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 99 (1999) 2192-2217
33. Severus W.E., Littman A.B., and Stoll A.L. Omega-3 fatty acids, homocysteine, and the increased risk of cardiovascular mortality in major depressive disorder. Harv Rev Psychiatry 9 (2001) 280-293
34. Sevincok L., Buyukozturk A., and Dereboy F. Serum lipid concentrations in patients with comorbid anxiety disorder and major depressive disorder. Can J Psychiatry 46 (2001) 68-71
35. Witzum J.L. The oxidation hypothesis of atherosclerosis. Lancet 344 (1994) 793-795
36. Wulsin L.R. Is depression a major risk factor for coronary disease? A systematic review of the epidemiologic evidence. Harv Rev Psychiatry 12 (2004) 79-93
37. Wulsin L.R., and Singal B.M. Do depressive symptoms increase the risk for the onset of coronary disease? A systematic quantitative review. Psychosom Med 65 (2003) 201-210
38. Zhang A., Vertommen J., Van Gaal L., and De Leeuw I. A rapid and simple method for measuring the susceptibility of low-density lipoprotein and very-low-density lipoprotein to copper-catalyzed oxidation. Clin Chim Acta 227 (1993) 159-173
39. Ziegelstein R.C., Fauerbach J.A., Stevens S.S., Romanelli J., Richter D.P., and Bush D.E. Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from myocardial infarction. Arch Intern Med 160 (2000) 1818-1823